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Abstract
22q11.2 deletion syndrome (22q11.2DS) is the most common chromosomal microdeletion 
disorder, estimated to result mainly from de novo non-homologous meiotic recombination events 
occurring in approximately 1 in every 1,000 fetuses. The first description in the English language 
of the constellation of findings now known to be due to this chromosomal difference was made in 
the 1960s in children with DiGeorge syndrome, who presented with the clinical triad of 
immunodeficiency, hypoparathyroidism and congenital heart disease. The syndrome is now known 
to have a heterogeneous presentation that includes multiple additional congenital anomalies and 
later-onset conditions, such as palatal, gastrointestinal and renal abnormalities, autoimmune 
disease, variable cognitive delays, behavioural phenotypes and psychiatric illness — all far 
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extending the original description of DiGeorge syndrome. Management requires a 
multidisciplinary approach involving paediatrics, general medicine, surgery, psychiatry, 
psychology, interventional therapies (physical, occupational, speech, language and behavioural) 
and genetic counselling. Although common, lack of recognition of the condition and/or lack of 
familiarity with genetic testing methods, together with the wide variability of clinical presentation, 
delays diagnosis. Early diagnosis, preferably prenatally or neonatally, could improve outcomes, 
thus stressing the importance of universal screening. Equally important, 22q11.2DS has become a 
model for understanding rare and frequent congenital anomalies, medical conditions, psychiatric 
and developmental disorders, and may provide a platform to better understand these disorders 
while affording opportunities for translational strategies across the lifespan for both patients with 
22q11.2DS and those with these associated features in the general population.
The eponymous description of DiGeorge syndrome — by the late Dr Angelo DiGeorge in 
1965 — included infants with absence of the thymus (thymic aplasia) and parathyroid 
glands (hypoparathyroidism)1. Congenital heart disease (CHD), especially involving the 
outflow tract2, was later added to the list of symptoms, contributing to the theory that a 
mechanism leading to the perturbation of the third and fourth pharyngeal arches during 
embryonic development might be involved. Interestingly, a similar phenotype can be 
associated with maternal diabetes3,4, maternal retinoic acid exposure5, single-gene disorders 
due to mutations in chromo-domain helicase DNA-binding protein 7 (CHD7; known as 
CHARGE syndrome)6,7 or mutations in T-box 1 (TBX1)8,9 and other chromosomal 
deletions, including 10p13–14 (REF. 10) and 11q23-ter11.
Over time, multiple aetiologies for DiGeorge syndrome were identified, beginning with a 
cytogenetically apparent 22q11.2 deletion in the early 1980s12,13. In the early 1990s, 
fluorescence in situ hybridization (FISH) studies using probes within the commonly deleted 
region identified submicroscopic 22q11.2 deletions as the most frequent cause of DiGeorge 
syndrome14,15 (FIG. 1). This preceded recognition that several seemingly unrelated 
conditions with overlapping phenotypic features similarly resulted from a 22q11.2 deletion, 
including: velocardiofacial syndrome15, conotruncal anomaly face syndrome16,17, and 
subsets of patients with Opitz G/BBB18 and Cayler cardiofacial19 syndromes20. Together, 
these observations suggest that the previously described clinical diagnoses were actually one 
and the same condition with a common aetiology21.
Today, it is well established that 22q11.2 deletion syndrome (22q11.2DS) involves 
microdeletions (approximately 0.7–3 million base pairs in size), resulting in an 
heterogeneous clinical presentation, irrespective of deletion size, that can be associated with 
multi-organ dysfunction including cardiac and palatal abnormalities, immune and 
autoimmune differences, endocrine, genitourinary and gastrointestinal problems, and brain 
involvement as evinced by variable developmental delays, cognitive deficits and 
neuropsychiatric illnesses (such as anxiety disorders and schizophrenia). In fact, 22q11.2 
deletion is the second-most common cause of CHD and developmental delays, and the most 
common cause of syndromic palatal anomalies. However, why the 22q11.2 region is 
particularly vulnerable to deletions remains under investigation. Furthermore, as a 
consequence of mechanistic understanding, the term DiGeorge syndrome is now reserved 
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for those rare patients who share clinical symptoms with 22q11.2DS but do not harbour a 
22q11.2 deletion. Otherwise, the broad phenotypic range of symptoms — including findings 
formerly associated with DiGeorge syndrome, velocardiofacial syndrome or conotruncal 
anomaly face syndrome — is referred to using the underlying cytogenetic nomenclature: 
22q11.2DS22,23. In this Primer, we focus on our current understanding of the 22q11.2DS 
phenotype and its genetic underpinnings.
Epidemiology
22q11.2DS is common and is the most frequent chromosomal microdeletion syndrome. The 
prevalence of this disorder has been estimated to range from 1 per 3,000 to 1 per 6,000 live 
births, based on the diagnosis of infants with major birth defects and a few population 
screening studies conducted between the early 1990s and early 2000s using FISH 
technology24–28. Today, most (90–95%) newly identified patients with 22q11.2DS are found 
to have de novo deletions — that is, neither parent has the 22q11.2 deletion29. However, 
owing to improved survival and thus higher reproductive fitness of individuals with 
22q11.2DS, the prevalence, especially of the inherited types, is expected to increase30,31. As 
22q11.2DS is a haploinsufficient disorder, approximately half of the children of individuals 
with 22q11.2DS will have the deletion. Similarly, smaller, atypical nested deletions between 
the low copy repeats on chromosome 22 (LCR22B–LCR22D and LCR22C–LCR22D 
deletions; FIG. 2) — not typically detected by clinically available FISH probes and, 
therefore, not included in the population studies from the 1990s — are often familial and 
have reduced penetrance and/or a milder expression; thus, these patients are more likely to 
reproduce. As a consequence, the proportion of patients ascertained at The Children’s 
Hospital of Philadelphia with a LCR22B–LCR22D deletion inherited from an affected 
parent is higher (60%) than it is for patients with the typical LCR22A–LCR22D deletion 
(~10%)32.
Two multicentre prenatal studies published in 2012 and 2015 reported 22q11.2 deletions in 1 
per 347 and 1 per 992 fetuses, respectively, using invasive prenatal testing33,34. Both studies 
included analyses of fetuses with or without abnormal ultrasonographic findings. The 
prevalence of the 22q11.2 deletion was approximately 1 in 100 for fetuses with major 
structural anomalies such as CHD, and was 1 per ~1,000 in seemingly anatomically normal 
fetuses (in both studies)33,34. The true live birth incidence remains to be defined by global 
newborn screening35,36. Notably, a small subset of neonates with 22q11.2 deletions have 
already come to attention through newborn screening for severe combined 
immunodeficiencies. 22q11.2 deletions have been identified in 1 per 169 children referred 
for clinical laboratory testing based on a suspicion of developmental disabilities37. 
Conversely, the 22q11.2 deletion is not found in samples of seemingly healthy individuals37 
as penetrance to develop clinical symptoms, frequently involving multiple organ systems, is 
high38.
Both sexes and all racial and ethnic groups are affected39. However, the deletion is slightly 
more often maternal in origin40 and non-white patients may be diagnosed less often, perhaps 
owing to less recognizable craniofacial features in these populations41,42.
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In the general population, 22q11.2 deletion is among the most common detectable cause of 
several conditions. A large proportion of patients with CHD have 22q11.2 deletions: 52% of 
those with interrupted aortic arch type B, 34% of those with truncus arteriosus, 16% of those 
with tetralogy of Fallot43 and ~5–10% of those with ventricular septal defects44. Other 
conditions associated with 22q11.2 deletions include velopharyngeal insufficiency (12.5–
30% of patients), cleft palate (10% of patients; cleft lip with or without cleft palate in 1–2% 
of patients)45–47, developmental disabilities (2–3% of patients)48 and schizophrenia (0.5–1% 
of patients)49,50. By contrast, the prevalence of the 22q11.2 deletion in other conditions with 
overlapping symptoms (for example, hypoparathyroidism) is as yet unknown. Ascertainment 
strategies will have a role in defining prevalence in these conditions. 22q11.2 deletions will 
be less likely identified in samples that deliberately or inadvertently exclude individuals with 
multiple medical or psychiatric features, or intellectual disabilities (that is, the very features 
that are common in 22q11.2DS), or in samples enriched for older individuals (given the 
premature mortality of the syndrome)51.
Premature mortality, although lower than suggested by early reports of DiGeorge syndrome, 
remains profound at all ages. About 4% of all infants with 22q11.2DS succumb, with 
mortality figures exceeding those for infants with similar malformations31,41. Cardiac 
defects, hypocalcaemia and airway malacia (in which cartilage defects lead to collapsibility 
of the airway) are risk factors for early death, with median age at death of 3–4 months31,41. 
In adults, premature death occurs at median age in the 40s; causes are multiple, including 
sudden unexplained death51, but are not necessarily related to cardiac defects or psychotic 
illness51. Larger studies are needed to more fully clarify mortality risks prospectively at all 
ages31,41,51.
Mechanisms/pathophysiology
22q11.2 deletion
The 22q11.2 region is one of the most structurally complex areas of the genome primarily 
due to several large blocks of LCRs or segmental duplications52–54 (FIG. 2). These LCRs 
are >96% identical, thereby making the locus vulnerable to meiotic error55,56. The two 
largest repeats, LCR22A and LCR22D, flank the typical 3-Mb 22q11.2 region that is 
hemizygous in ~85% of patients52,53. The 22q11.2 deletion results from nonallelic 
homologous recombination between LCR22A and LCR22D (FIG. 3). The same mechanism 
leads to the proximal (centromeric) nested 1.5-Mb (LCR22A–LCR22B) or 2-Mb (LCR22A–
LCR22C) deletions (FIG. 2). Patients with these nested deletions have major phenotypic 
features in common with patients with the typical LCR22A–LCR22D deletion52–54. 
However, the frequency of the nested proximal deletions accounts for only 5–10% of all 
22q11.2 deletions52,53,57. Likewise, distal nested (LCR22B–LCR22D and LCR22C–
LCR22D) deletions lead to overlapping phenotypic features, including conotruncal cardiac 
anomalies, palatal defects and developmental differences, but the clinical features are less 
penetrant than those of the typical LCR22A–LCR22D deletion. Moreover, these deletions 
(LCR22B–LCR22D and LCR22C–LCR22D) are more frequently inherited32,58.
Much remains to be learned about the underlying mechanisms of vulnerability to non-allelic 
homologous recombination and the de novo occurrence of the 22q11.2 deletion40. The 
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completeness and accuracy of the human genome reference assembly remains a major 
challenge to these research efforts59,60.
Furthermore, 22q11.2 hemizygosity alone cannot explain the genetic mechanism of the 
highly variable phenotypic expression of 22q11.2DS. Proposed mechanisms, in addition to 
the combined effect of this multi-gene deletion61–65 (FIG. 2) and stochastic phenomena, 
include the sensitivity of individual genes within the 22q11.2 region to gene dosage66,67, 
variants in genes on the intact 22q11.2 (REF. 68) and additional ‘modifying’ variants outside 
the 22q11.2 region, involving both protein-coding genes and regulatory mechanisms67,69–73. 
Researchers are currently evaluating common and rare single-nucleotide variants as well as 
copy number variations in genome-wide assays to explain these findings. Parental age and 
parental origin of de novo deletions seem to have no discernible phenotypic effect40,74. 
However, inherited deletions may result in a more-severe cognitive phenotype, perhaps 
related to a combination of socioeconomic factors and heritable components contributed by 
the unaffected parent75.
Developmental aspects of 22q11.2DS
The mouse is the main organism used for investigating developmental aspects of the 
syndrome, as its developmental anatomy is similar to that of a human and it is possible to 
generate individual gene mutations as well as multi-gene deletions63. Conditional 
mutagenesis studies have also examined the timing and/or tissue-specific requirements of 
certain genes76 and gene dosage requirements using an allelic series approach66,77. 
Importantly, as some phenotypes only become apparent at later ages63, conditional mutants 
allow bypass of the early embryonic lethality that is observed in some constitutive null 
mutants. Mouse models have also contributed greatly to understanding expression in 
developing and adult brain tissue61,63,67,78–82.
Much of the pathology related to typical congenital physical features associated with 
22q11.2DS can be ascribed to problems with the morphogenesis and subsequent abnormal 
function of pharyngeal arch system derivatives, including the craniofacial structures, the 
thymus, the parathyroid glands, the aortic arch and the cardiac outflow tract (FIG. 4). These 
structures receive contributions from all three classic germ layers of the embryo — the 
endoderm, mesoderm and ectoderm — together with neural crest cells derived from the 
closing neural tube.
Pharyngeal mesoderm progenitor cells give rise to craniofacial muscles and second heart 
field derivatives, including the cardiac outflow tract64,78. The facial bones and bony palate 
are variously derived from neural crest cells or the anterior mesoderm. The parathyroid 
glands and the thymus derive from tissue interactions between the pharyngeal endoderm and 
neural crest cells76,83. Defects in parathyroid gland development lead to hypocalcaemia, and 
defects in the developing thymus lead to immune deficiencies.
Congenital cardiac anomalies are related to defects in the arteries formed within the 
pharyngeal apparatus and in the cardiac outflow tract. As for the other affected tissues (the 
thymus, parathyroid glands and facial structures), there is a very close relationship between 
adjacent cell types. Mesoderm-derived endothelial cells and neural crest cells participate 
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directly in the formation of the pharyngeal arch arteries. Signals from the pharyngeal 
ectoderm and a direct cellular contribution from the neural crest are required for remodelling 
into the mature aortic arch. Reciprocal interactions between the second heart field and neural 
crest cells are essential for outflow tract remodelling84–87. The most specific cardiovascular 
defects associated with 22q11.2DS are interrupted aortic arch type B (ascribed to aplasia of 
the left fourth pharyngeal artery)88 and tetralogy of Fallot (related to defects in the 
development of the pulmonary infundibulum).
DNA sequences in the 22q11.2 region
There are 90 known or predicted genes present in the typical 3-Mb 22q11.2 locus that are 
hemizygously deleted — including 46 protein-coding genes and seven microRNAs 
(miRNAs), ten non-coding RNAs (including one read-through transcript) and 27 
pseudogenes (per genome build GRCh37 — a human reference sequence produced by the 
Genome Reference Consortium)89. A subset of genes, as provided in the University of 
California Santa Cruz (UCSC) gene prediction track, are shown in FIG. 2. The most studied 
gene of interest in the 22q11.2 deletion region is TBX1, encoding a T-box transcription 
factor. TBX1 was found to be a crucial gene in the LCR22A–LCR22B region using multiple 
mouse model approaches90–92. Heterozygous loss-of-function mutations of Tbx1 in the 
mouse result in partially penetrant cardiovascular, thymic and parathyroid defects that are 
reminiscent of congenital defects in 22q11.2DS91,92. Tbx1-null mice are embryonic lethal 
with a persistent truncus arteriosus, cleft palate and absence of the thymus and parathyroid 
glands. Conditional mutagenesis of Tbx1 in the mesoderm, pharyngeal surface ectoderm or 
endoderm each leads to an overlapping subset of the abnormalities mentioned above93,94, 
demonstrating the complexity of the tissue interactions that are required for morphogenesis 
of the pharyngeal derivatives95. Tbx1 expression has not been detected in neural crest cells, 
and neural crest cell-specific knockout mice have no discernible phenotype. However, neural 
crest cell patterning is affected in Tbx1-conditional mutants of both the surface ectoderm96 
and the second heart field97. At the cellular level, mouse models have also been important in 
the detection of reduced proliferation and premature differentiation of progenitor cells 
expressing Tbx1 (REF. 98). Tbx1 has been implicated in brain microvascular development99 
and may play some part in cognitive and behavioural deficits100.
Another gene of interest is DGCR8, encoding the DGCR8 microprocessor complex subunit 
(also known as Pasha), a double-stranded RNA-binding protein that mediates the biogenesis 
of miRNAs. This observation implicates an miRNA-related mechanism in 
22q11.2DS81,82,101. miRNAs are small non-coding RNAs that regulate the expression of 
target genes by binding to specific sites in mRNAs for translational repression or 
degradation. In mouse models, heterozygosity of Dgcr8 results in neuronal deficits that are 
characteristic of 22q11.2DS, whereas inactivation of both alleles in neural crest cells101 
results in heart defects101,102. Subtle alterations in miRNA expression levels can have 
profound effects on brain development and plasticity, especially involving synapses103,104. 
Recent studies propose that DGCR8 may play a part in modifying the expression of genes 
outside of the 22q11.2 deletion region that contribute to the neuropsychiatric and other 
phenotypes associated with 22q11.2DS63,72,101,105.
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In addition to DGCR8-related changes in miRNAs, the high density of miRNAs in the 
22q11.2 deletion region and the accumulative insight into their function indicate that these 
functional non-coding RNAs may themselves have a role in the variable expression of 
22q11.2DS73,105,106. These effects on expression are likely to involve not only the central 
nervous system (CNS) but also the cardiovascular system and other aspects of embryonic 
development73,105,106.
Much evidence has been accumulated for a role of other individual 22q11.2 region protein-
coding genes in major phenotypes of 22q11.2DS. These genes include v-crk avian sarcoma 
virus CT10 oncogene homologue-like (CRKL), encoding a cytoplasmic adaptor protein to 
growth factor signalling, which maps to the LCR22B–LCR22D region107 and acts in a 
dosage-sensitive manner108. Human and mouse model data indicate that haploinsufficiency 
of CRKL could be responsible for the aetiology of cardiac anomalies in individuals with 
nested distal deletions and seems to modulate natural killer cell function109. Another gene, 
synaptosomal-associated protein 29 kDa (SNAP29), encodes a soluble SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) protein that is predicted to 
mediate vesicle fusion at the endoplasmic reticulum or Golgi apparatus membranes, is 
highly expressed in myelinating glial cells, is required for lamellar body formation in the 
skin, and is indirectly required for β1-integrin endocytosis and cell migration. Mutations in 
this gene have been associated with cerebral dysgenesis, neuropathy, ichthyosis and 
palmoplantar keratoderma (CEDNIK), Kousseff and Opitz G/BBB syndromes68. Scavenger 
receptor expressed by endothelial cells 2 protein (SREC2), encoded by SCARF2, contains 
putative epidermal growth factor-like domains in its extracellular domain, along with 
numerous positively charged residues in its intracellular domain, indicating that it may be 
involved in intracellular signalling. Homozygous or compound heterozygous mutations of 
SCARF2 underlie Van den Ende–Gupta syndrome characterized by severe contractural 
arachnodactyly and distinctive facial dysmorphism, including triangular face, as well as 
skeletal anomalies110.
With respect to neuropsychiatric phenotypes, there are multiple gene candidates as the 
majority of genes in the 22q11.2 deletion region are expressed in the brain89. COMT 
encodes catechol-O-methyltransferase, one of several enzymes that degrade catecholamines, 
including dopamine. Its activity is of particular importance in brain regions with low 
expression of the presynaptic dopamine transporter, such as the prefrontal cortex. A 
polymorphism associated with a different level of enzymatic activity (that is, the COMT 
Val/Met functional polymorphism) has been explored in 22q11.2DS with respect to 
cognition and susceptibility to schizophrenia. However, multiple studies have found no 
association of the COMT functional Val/Met common allele with schizophrenia in adults 
with 22q11.2DS111–113. There may be some effects of this common variant on frontal lobe 
functioning and anatomy in 22q11.2DS111, although results for overall intellect are 
mixed114. PRODH, encoding the enzyme proline dehydrogenase, which breaks down 
proline, has also been studied, in part because pathogenetic mutations in PRODH are known 
to cause type I hyperprolinaemia, which in severe forms can cause seizures and intellectual 
disability. Approximately one-third of patients with 22q11.2DS have increased levels of 
proline115, and several studies, although not all, have shown significant associations between 
high proline levels and various brain outcome measures in 22q11.2DS116–119. However, 
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studies of common variants in PRODH, as for those in COMT, in 22q11.2DS show 
contradictory results with respect to risks for intellectual disability or schizophrenia114. 
Zinc-finger DHHC-type-containing 8 (ZDHHC8), which encodes a palmitoyltransferase, has 
shown interesting results in studies of mutant mouse models, with effects on axonal growth 
and terminal arborization, and potential functional implications for synaptic connections and 
working memory62. Another 22q11.2 region candidate is RANBP1, encoding a binding 
protein for the small GTPase Ran. As a regulator of the Ran complex, this protein has 
multiple functions — including cilia formation and modulation of mitosis — that may 
contribute to the CNS and other phenotypes of 22q11.2DS117. Evidence for a role in 
neurogenesis places RANBP1 as a candidate for the cortical circuits implicated in disorders 
associated with 22q11.2DS, such as attention-deficit disorders, autism and 
schizophrenia79,117.
Together with the miRNA mechanism implicated by DGCR8, and downstream effects of 
dosage changes in individual genes such as TBX1, there is increasing evidence for effects of 
the 22q11.2 deletion on, and interaction with, signalling pathways and proteins encoded by 
multiple genes outside of the 22q11.2 deletion region. For example, mitogen-activated 
protein kinase 1 (Mapk1)120 and hypermethylated in cancer 2 (Hic2)121, are of interest for 
cardiovascular and other aspects of embryonic development in mice. Loss of Tbx1 may be 
partially rescued by hemizygosity of Trp53, implicating histone methylation as a mechanism 
and suggesting potential pharmacological strategies that could compensate for 
developmental defects associated with 22q11.2 deletions98. Defective cortical circuitry and 
some abnormalities of signalling, for instance, in Sonic Hedgehog and CXC chemokine 
receptor 4 (Cxcr4)– CXC chemokine ligand 12 (Cxcl12; also known as Sdf1) signalling, 
which are important in interneuron migration, have been detected in the brains of mouse 
deletion models that may involve a DGCR8-mediated miRNA mechanism and have 
relevance for schizophrenia in the general population79,122.
The plethora of signalling and other pathways that are affected by the hemizygosity of the 
22q11.2 deletion region in model systems may be valuable to help to identify modifiers of 
the 22q11.2DS phenotype in humans63,79,114,122, perhaps particularly for genes outside of 
the 22q11.2 deletion region123,124. These studies also promise to elucidate mechanisms 
underlying the variable phenotypic expression related to other pathogenetic copy number 
variations and to identify genes involved in the mechanism of common complex conditions, 
such as congenital cardiac and palatal anomalies, schizophrenia, Parkinson disease and 
many others, emphasizing the importance of 22q11.2DS as a model for these diseases in the 
general population.
Diagnosis, screening and prevention
Clinical manifestations
Clinical manifestations that urge for diagnostic testing vary by age. In infancy or childhood, 
typical symptoms include some combination of congenital heart defects, chronic infection, 
nasal regurgitation, hypernasal speech, hypocalcaemia, feeding difficulties, developmental 
and language delays, behavioural differences and learning disabilities20,22,39,125. Renal 
abnormalities, laryngo-tracheo-oesophageal abnormalities, hypothyroidism, intrauterine 
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growth retardation, short stature, skeletal differences such as vertebral anomalies, club feet, 
polydactyly and scoliosis, thrombocytopenia, hearing loss, microcephaly, idiopathic seizures 
and hypotonia are less frequent (FIG. 5).
In adolescence and adulthood, behavioural abnormalities, in many instances indicative of 
(emerging) psychiatric illness, can lead to the diagnosis125, frequently (but not always) with 
a history of associated medical and developmental differences, such as hypocalcaemia or 
learning difficulties29. The presence of subtle but characteristic facial features can assist with 
identification at any age (FIG. 6). However, the opportunity for diagnosis can be missed 
when typical craniofacial and other typical congenital features such as cardiac or palatal 
defects are absent. This can be the case even when presenting with other high-prevalence 
conditions associated with 22q11.2DS, such as hypocalcaemia or psychotic illness. Major 
medical centres when less experienced with caring for patients with 22q11.2DS are not 
exempt from overlooking the 22q11.2DS diagnosis in part owing to the broad phenotypic 
variability22,126. Some adults are only diagnosed following the birth of an affected child29.
The overall prevalence of considerable medical problems varies by age and ascertainment. In 
childhood, the triad of DiGeorge syndrome (although with highly variable degree of 
severity) is often ascertained: immunodeficiency (~75% of patients); congenital cardiac 
anomalies (~75% of patients); and hypocalcaemia due to hypoparathyroidism (~50% of 
patients). Other complications include palatal abnormalities (~75% of patients); manifest 
gastrointestinal, feeding and swallowing problems (~30% of patients); and genitourinary 
anomalies including renal agenesis (~30% of patients) (FIG. 5). Phenotypic expression is 
highly variable and ranges from severe life-threatening conditions to only a few less-severe 
associated features23,114. Additional complexities include considerable interfamilial and 
intrafamilial variability127, even between identical twins29. Diagnosis on clinical grounds of 
a child with mild features requires familiarity with the condition. Dual diagnosis of other 
unrelated conditions (for example, ‘café-au-lait’ spots due to neurofibromatosis, skeletal 
disproportion due to achondroplasia or Marfan syndrome, or deep palmar and plantar 
creases due to trisomy 8 mosaicism) is possible, especially when features appear unusual, as 
22q11.2DS is common.
Cardiovascular abnormalities—Cardiovascular abnormalities become evident in the 
prenatal or neonatal period and are often the initial manifestation that leads to diagnosis23. 
Most abnormalities are conotruncal heart defects — defined as malformations of the outflow 
tract — and include tetralogy of Fallot (with or without pulmonary atresia), truncus 
arteriosus, interrupted aortic arch type B (between the left carotid and the left subclavian 
arteries) and ventricular septal defect. Anomalies of the aortic arch and/or of the pulmonary 
arteries may occur as isolated entities (~40%) or in association with conotruncal defects 
(~60%)44, contributing to the relative specificity of the cardiovascular patterns of this 
syndrome86–88. Aortic arch anomalies most frequently include a right-sided or a double 
aortic arch with or without aberrant subclavian arteries sometimes resulting in a vascular 
ring (~13%)128. Pulmonary artery anomalies include diffuse hypoplasia and discontinuity 
with or without major aorto-pulmonary collateral arteries. Approximately 10% of paediatric 
patients have aortic root dilation with unclear clinical significance129. Other types of CHD 
are rarer in patients with 22q11.2DS39. Cardiovascular defects that are less obvious, such as 
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a vascular ring, may not be diagnosed until the patient is older and presents with respiratory 
symptomatology128. Similarly, a ductal-dependent lesion, for instance, an interrupted aortic 
arch type B, might escape neonatal detection in the absence of an audible murmur, pass 
neonatal screening with pulse oximetry in the presence of a patent ductus arteriosus and 
might only present in extremis, which increases overall morbidity and at times mortality. 
Overall, CHD represents the main cause of mortality (~87%)29,31 in children with 
22q11.2DS.
Immunodeficiency—Immunodeficiency affects up to 75% of paediatric patients with 
22q11.2DS owing to thymic hypoplasia and impaired T cell production7,23,29,130. However, 
the condition is heterogeneous, ranging from patients with normal thymic development and 
normal T cell production to a small subset of patients with absent T cell 
production22,29,131,132. Manifestations include chronic infections130,131,133, impaired 
humoral (antibody) immune response resulting in poor response to vaccines134,135, IgA 
deficiency136, allergy and asthma5,137,138. Autoimmune diseases such as juvenile 
rheumatoid arthritis139, idiopathic thrombocytopenia140, haemolytic anaemia141 and thyroid 
disease142 are collectively common7,22,29,130–136,138,139.
Testing is required to define the immune dysfunction. Assessment of thymic function is best 
performed by analysing peripheral blood T cells by flow cytometry. Imaging of the thymus 
is not accurate as the size, absence or presence of thymic tissue does not predict individual 
immune function, although when absent, it may lead to diagnostic studies both prenatally 
and postnatally143. Current recommendations support an early assessment of T cells using a 
flow cytometry panel that includes total T cells (CD3), naive T cells (usually CD4/
CD45RA), memory T cells (usually CD4 or CD45RO), B cells (CD19) and natural killer 
cells (CD3−CD56+CD16+)36,92,134,144. The absolute counts of T cells should be analysed 
rather than percentages. T cell lymphocytopenia can also be detected in newborn screens for 
severe combined immunodeficiencies.
Palatal abnormalities—Only 11% of paediatric patients have overt cleft palate, of whom 
1–2% have cleft lip or cleft palate, and even fewer have Pierre Robin 
sequence20,29,39,145,146. However, ~65% of patients have milder but often medically 
actionable manifestations such as: occult submucosal cleft palate, bifid uvula and 
velopharyngeal dysfunction, making the palatal diagnosis more challenging in the prenatal 
or early-neonatal period. Initial signs may only include a history of polyhydramnios (an 
excessive amount of amniotic fluid surrounding the fetus) or nasal regurgitation (that is, 
secretions, food or liquids coming through the nose with feeding and spitting up in young 
children or reflux of thin liquids into the nasal cavity in older individuals). Later, symptoms 
include abnormal nasal resonance and nasal emissions (air escape through the nasal passage 
with speech). Compensatory articulation errors are often present, which can worsen speech 
intelligibility in children with velopharyngeal dysfunction. In older children and adults, 
recurrent and chronic sinus infections may be a sign of nasopharyngeal reflux resultant from 
repeated contamination of the nasal cavity. Persistent otorrhoea with myringotomy tubes in 
place may also be due to nasopharyngeal reflux20,22,29,39,145,147–150. Additional craniofacial 
features that might facilitate diagnosis include asymmetric crying faces (found in 14% of 
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patients with 22q11.2DS), auricular (ear) anomalies with or without hemifacial 
microsomia20, craniosynostosis and characteristic facial features, such as hooded eyelids and 
a nasal dimple151 (FIG. 6).
Endocrine abnormalities—Hypoparathyroidism, with hypocalcaemia as a consequence, 
is found in >50–65% of patients with 22q11.2DS152,153. Symptoms of hypocalcaemia can 
include tetany, seizures, feeding difficulty, stridor and fatigue. Transient neonatal 
hypocalcaemia or new-onset hypocalcaemia often occurs or recurs during times of stress 
(such as during illness, perioperatively or during adolescence and pregnancy)22,152–154. 
Additional endocrine manifestations that may also be features of 22q11.2DS include: 
hypothyroidism in children and ~20% of adults, and hyperthyroidism in children142 and 
~5% of adults; and growth hormone deficiency, intrauterine growth retardation (~4% of 
patients) and short stature (~15% of patients)22,126,152–157.
Gastrointestinal abnormalities—Considerable gastrointestinal abnormalities are found 
in ~30% of patients and can result in substantial feeding and swallowing problems that 
might necessitate tube-feeding158. In early childhood, gastrointestinal complications can 
present as gastro-oesophageal reflux disease, oesophageal dysmotility, nasopharyngeal 
reflux, vomiting and constipation158. Serious complications include oesophagitis, aspiration, 
failure to thrive, malnutrition, feeding refusal and respiratory symptomatology, such as 
choking and recurrent pneumonia145,158. Importantly, CHD may be erroneously blamed for 
feeding difficulties. Other possible causes that should be taken into account include 
endocrine (aberrant calcium and/or thyroid hormone levels), CNS (hypotonia, 
polymicrogyria and/or cerebellar), respiratory (congestion, increased work of breathing, 
vascular ring and/or laryngeal anomaly) and gross motor (posture, oral motor coordination 
and tongue retraction) dysfunctions158. Rare but important complications of 22q11.2DS 
include intestinal malrotation or non-rotation, imperforate anus, Hirschsprung disease and 
oesophageal atresia or tracheo-oesophageal fistula159.
Genitourinary abnormalities—Approximately one-third of patients have genitourinary 
abnormalities20,22,23,27,29,39,153,160 including: bilateral or unilateral renal agenesis25,161,162, 
dysplastic or cystic kidneys161,162, duplicated collecting system161,162, 
hydronephrosis161,162, cryptorchidism18, hypospadias18, absent uterus163 or inguinal 
hernia164.
Other—Other important somatic associations include major malformations such as: 
congenital diaphragmatic hernia (~1%), laryngeal anomalies (clefts or webs), eye 
abnormalities (sclerocornea, retinal coloboma or microphthalmia), choanal atresia, 
polymicrogyria and neural tube defects22,165,166. Preaxial and postaxial polydactyly, 
camptodactyly, arachnodactyly and radial ray defects may be observed in the upper 
extremities, whereas 2–3 syndactyly, overlapping toes, hammer toes, postaxial polydactyly 
and club foot may be observed as lower extremity differences167. Anomalies are also 
observed in the cervical spine (platybasia, fusion and/or block, anomalous dens, C2 swoosh, 
increased motion) and thoracic vertebrae168 (butterfly vertebrae), eyelids (ptosis and hooded 
eyelids), eye (hypertelorism, tortuous retinal vessels, posterior embryotoxon and upslanting 
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palpebral fissures) and umbilical hernia (especially in non-white patients)151. Conditions 
that require ongoing surveillance include scoliosis (~30%); sensorineural and conductive 
hearing loss or cochlear abnormities; and rarely malignancies that include hepatoblastoma, 
Wilms tumour, renal cell carcinoma, thyroid carcinoma, leukaemia, neuroblastoma and 
melanoma22,23,29,41,169. Treatable later-occurring conditions include unprovoked seizures 
(~15%), early-onset Parkinson disease and psychiatric illnesses (~60%)126,153,170.
Developmental delays—Developmental and educational concerns are frequently 
reported in association with 22q11.2DS. Gross and fine motor difficulties171, and expressive 
language delays and speech problems dominate in infants and toddlers172. Children with 
22q11.2DS often demonstrate a significant delay in language onset; an early study indicated 
that ~70% of children did not speak or used only a few words or signs at 24 months of age 
or older172. Speech deficits should be discriminated from language disorders as the former 
often improves after velopharyngeal corrective surgery, whereas language disorders may 
occur independently of palatal findings172. Intelligence in children and adolescents follows a 
normal distribution that is comparable to the general population173,174. However, mean IQ is 
only ~70, with about two-thirds of individuals falling in the IQ range of 55–85, compared 
with the reference IQ range of 85–115 (mean: 100) in the typically developing population. 
Thus, learning difficulties are very common in preschool and primary school, especially 
within the domains of mathematics175,176 and language comprehension177. More-severe 
levels of intellectual disability are uncommon178. However, paediatric patients with 
secondary insults (for example, following cardiac arrest, prolonged hypocalcaemia or 
neonatal seizures) or primary brain malformations (for example, polymicrogyria) can have a 
poorer cognitive prognosis68,179. Several studies indicate that cognitive development varies 
with divergent trajectories125,180 and that the level of intellectual ability is not necessarily 
stable across the lifespan of the patient. Although IQ is generally considered to be a more or 
less stable trait in the typically developing youth, an average decline of 7 full-scale IQ points 
is observed in individuals with 22q11.2DS between 8 years and 24 years of age181.
Psychiatric disorders—Individuals with 22q11.2DS are at an increased risk for 
developing several psychiatric disorders; the prevalence of anxiety, attention-deficit and 
autism spectrum disorders is increased in children with 22q11.2DS182. Anxiety disorders are 
also profoundly increased in adults with 22q11.2DS183. Conversely, bipolar disorder does 
not seem to be increased, and it remains unclear if major depressive disorder shows greater 
prevalence than in the general population182,183. As for any phenotypic feature of 
22q11.2DS, prevalence is likely to be influenced by ascertainment bias and the use of 
diverse assessment methods. Approximately 25% of individuals with 22q11.2DS are 
diagnosed with schizophrenia112,184, and, in turn, the 22q11.2 deletion can be found in ~1 
per 100–200 individuals with schizophrenia49, making 22q11.2 deletion the strongest known 
molecular genetic risk factor for schizophrenia. The manifestation of schizophrenia in 
patients with 22q11.2DS does not differ from other types of schizophrenia with respect to 
prodromal stage, age of onset (although a prospective study of youths is needed), core signs 
and symptoms, treatment response and cognitive profile apart from an overall lower 
IQ74,112,114,185–189. In addition to standard categorical classifications, dimensional 
assessment of psychiatric and cognitive symptoms190 can be helpful in understanding the 
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individual’s profile of strengths and weaknesses. Education about associated psychiatric 
conditions that arise early in life (including autism spectrum, attention-deficit and anxiety 
disorders) as well as in adolescence and later (for example, psychotic illnesses and anxiety 
and mood disorders), and their early signs and symptoms, can assist the family and facilitate 
prompt access to psychiatric assessment, diagnosis and treatment22,126.
Reproduction—With the current standard of clinical care, survival of patients with 
22q11.2DS to reproductive age is the norm29. Reproductive fitness for women with 
22q11.2DS, in the absence of schizophrenia or intellectual disability, is similar to that of 
their unaffected sisters and general population expectations30. Disproportionately reduced 
reproductive fitness of men with 22q11.2DS might contribute to an observation of excess 
maternal transmission of 22q11.2 deletions30. However, reproductive health and decision 
making present challenges for patients, their families and clinicians191. The ability to act as 
an independent parent may be affected by the complex phenotypic expression of the 
syndrome, including psychiatric and neurodevelopmental features22,29. In addition, features 
of the syndrome may be important considerations for pregnancy planning. For example, the 
use of necessary but teratogenic medications (such as anticonvulsants, for example, 
valproate or phenytoin) can increase the risk for birth defects, and the presence of CHD in 
the expectant mother can increase the risk for pregnancy complications. As for all women 
with CHD considering pregnancy, recommendations suggest stratifying the patient’s risk by 
integrating the specific defect with the presence of additional risk factors (such as a history 
of arrhythmias, the need for systemic anticoagulation and smoking, among other 
factors)191–193.
Diagnostic tests
Historically, the most frequent diagnostic test used to identify a 22q11.2 deletion involved 
FISH, using a probe mapping to the LCR22A–LCR22B region14,15(FIG. 2). Thus, nested 
deletions excluding the LCR22A–LCR22B region (that is, LCR22B–LCR22D and 
LCR22C–LCR22D deletions) can be detected using customized FISH probes from the 
LCR22B–LCR22D region or more easily using clinically available whole-region 
methodologies, such as multiplex ligation-dependent probe amplification194,195 or single-
nucleotide polymorphism microarrays. As genome-wide microarrays detect pathogenic copy 
number variants on all chromosomes, this methodology has the added benefit of not 
introducing bias by requiring pre-selection of a specific genomic region. This may be 
especially beneficial for those patients with few clinical features or multiple atypical 
features, with less experienced health care providers58,108.
Screening
Prenatal genetic counselling for couples in which one partner has the 22q11.2 deletion with 
an a priori 50% recurrence risk includes discussions about non-invasive screening (including 
fetal ultrasonography and echocardiography), definitive 22q11.2 deletion studies through 
chorionic villus sampling or amniocentesis, use of donor gametes, pre-implantation genetic 
diagnosis using in vitro fertilization and/or adoption. All parents of children with 22q11.2DS 
should be tested to identify mildly affected individuals and those with low-level somatic 
mosaicism. As germline mosaicism196 confers a recurrence risk above that of the general 
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population for those couples in which neither parent has the 22q11.2 deletion, these couples 
may choose non-invasive methodologies, such as non-invasive prenatal screening and fetal 
imaging, or definitive diagnostic testing in subsequent pregnancies. Screening for 22q11.2 
deletions can be included when invasive testing is already being considered for another 
reason, such as advanced maternal age. However, in many instances, parental anxiety is 
enough to support these investigations.
Currently, screening for the 22q11.2 deletion in individuals from the general population is 
considered when anatomic abnormalities, for example CHD, are identified on fetal 
ultrasonography, or when a fetus is considered high risk following non-invasive prenatal 
screening197. Invasive prenatal studies, using newly available methods such as single-
nucleotide polymorphism microarrays, can diagnose a fetus with 22q11.2DS with or without 
prenatally recognizable features. Moreover, some parents are identified with 22q11.2DS 
only following ascertainment in their fetus29 or through non-invasive prenatal screening in 
previously undiagnosed mothers. Long available, fetal ultrasonography can reveal several 
22q11.2DS-related findings, including CHD, cleft palate, renal anomalies, polyhydramnios, 
polydactyly, diaphragmatic hernia, club feet, tracheo-oesophageal fistula and neural tube 
defects. Should such findings lead to prenatal diagnostic testing to rule out aneuploidy (for 
example, trisomy 13, 18 and 21), the addition of 22q11.2 deletion studies as an adjunct to 
standard cytogenetics should be considered29,198. Early diagnosis may facilitate the ability 
to prevent neonatal seizures due to hypocalcaemia179.
Management
Management of 22q11.2DS requires an individualized, multidisciplinary and coordinated 
care plan that takes into account the associated features of the patient. An increasing 
emphasis of many health care systems on acute, readily managed, cross-sectional, ‘one-size-
fits-all’ care in silos can be problematic. A broad flexible perspective, embracing multi-
system issues that are often chronic and require longitudinal coordinated management, in the 
context of a frequently changing clinical picture and in the context of social and/or learning 
difficulties is required to manage patients with 22q11.2DS.
The International 22q11.2DS Consortium was formed in 2006 with a goal of developing 
management parameters (BOX 1). Guidelines were proposed for children and adults with 
22q11.2DS22,126. The consortium currently operates under the umbrella of the 22q11.2 
Society, a professional body that was established in 2013 to support basic science and 
clinical collaborations and to maintain access to contemporary guidance for health care 
providers.
Cardiovascular system
CHD is typically diagnosed prenatally or during the first days to months of life199–202. The 
diagnostic tools and surgical treatment are, in general, the same as for any child with 
CHD199,200. However, 22q11.2DS is associated with longer hospital stays, greater resource 
use and more medications at discharge201,202. Specific perioperative care should be focused 
on the prevention of hypocalcaemia, immunological depression, vasomotor instability, 
bronchospasm and airway bleeding199,201,202. In addition to standard antimicrobial 
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prophylaxis, an antifungal agent may be considered199. The results of surgery are usually 
good, and operative mortality is comparable to that of other patients199–202. However, 
overall mortality for those with 22q11.2DS exceeds that for non-syndromic individuals with 
similar cardiac defects31.
Lifetime surveillance is mandatory for patients with major CHD, with many patients 
requiring cardiac catheterization and a subgroup interventional procedures and/or repeat 
cardiac surgery126,203,204. Specific treatments relate to each cardiac defect in agreement with 
international protocols203. Residual valve lesions and outflow obstruction, ventricular 
function, arrhythmias, heart failure, aortic root dilatation and bacterial endocarditis should 
be monitored126,129,203,204. Cardiac components of premature and sudden death should be 
prevented, as much as possible, in all patients51,126,129,203,204.
Women with 22q11.2DS and CHD seeking advice about pregnancy should be evaluated 
using standard risk assessments developed for all women with CHD, given the risks for 
maternal, fetal and neonatal complications and mortality192,193. Although severe forms of 
systemic ventricular dysfunction, cyanosis and/or pulmonary hypertension pose excessive 
risks, in most other situations, pregnancies may be managed safely from a cardiac 
perspective, given that access to specialized high-quality care during pregnancy and delivery 
is guaranteed192,193. However, general risks relating to pregnancies in which the fetus has a 
22q11.2 deletion, such as small size and prematurity, remain increased157.
Immune system and autoimmune conditions
Management of immune deficiency ranges from a thymus transplant (rare) to no 
intervention66. Assessment of newborns allows for the identification of infants with no 
CD45RA T cells who will require a thymus transplant or a matched T cell transplant. Early 
assessment also provides guidance for live viral vaccine administration. In the setting of very 
low T cells, patients will require protective isolation and live viral vaccines should not be 
given. Patients with no CD45RA T cells require prophylaxis against pneumocystis. T cell 
counts should be reassessed at approximately 1 year of age, before administration of the 
measles, mumps and rubella vaccines and the Varivax vaccine. Data support a CD4 T cell 
count of >500 cells per µl as being the lower limit for safe vaccine 
administration135,146,205–207. A small percentage of patients will develop antibody 
deficiencies208, but the patient characteristics that predispose to this condition are not yet 
clear; periodic monitoring seems prudent. Patients with hypogammaglobulinaemia can be 
treated with immunoglobulin replacement.
Infections are often problematic across the lifespan of an individual with 22q11.2DS. Young 
children with 22q11.2DS have very frequent sinopulmonary infections, owing to immune 
deficiency, unfavourable anatomy and immune immaturity137. In addition, patients are at 
increased risk of allergies, and this may also contribute to sinopulmonary infections137. 
Infections seem to correlate with the humoral immune deficiency in adults209. The approach 
to recurrent infections in children and adults involves minimizing the anatomical 
contribution with ear tubes, sinus rinses, treatment of concomitant allergies and, in infants, 
feeding practices that discourage pooling of formula in the pharynx. Prophylactic antibiotics 
represent an approach that can provide some relief, and immunoglobulin replacement should 
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be offered to those with demonstrated humoral defects. Patients with autoimmune diseases 
are typically managed using strategies that are appropriate for patients with autoimmune 
diseases without 22q11.2DS, but immune suppression should be minimized210.
Palatal disorders
Overt cleft palate and cleft lip or cleft palate in patients with 22q11.2DS are addressed 
routinely in very early childhood using treatments that are, in general, the same as for those 
of any child with clefts211. Velopharyngeal dysfunction can lead to maladaptive articulation 
patterns with unintelligible speech, resulting in frustration that affects psychosocial 
development. This often causes parental distress and an eagerness to proceed with surgical 
interventions. The goals of surgery, generally at approximately 4–6 years of age, include 
normal speech production, effective communication and improved quality of life (QOL). An 
individualized treatment plan to optimize speech outcomes while minimizing perioperative 
and postoperative complications requires an initial assessment of speech and language 
status.
Too little speech may preclude obtaining an adequate sample for surgical decision making, 
thus pre-surgical speech therapy with total communication strategies is recommended 
beginning in infancy. In addition, velopharyngeal imaging using nasendoscopy or multi-view 
videoflouroscopy is typically required to determine the pattern, motion and degree of 
velopharyngeal closure before making a surgical plan. Additional considerations include 
airway size and preoperative co-morbid conditions, including visibly enlarged tonsils or 
adenoids, obstructive sleep apnoea212, asthma, cervical spine instability, carotid 
displacement, and cardiac, endocrine, haematological and feeding problems; ascertainment 
of developmental, emotional and behavioural status is also important. Patients also benefit 
from perioperative calcium monitoring and preoperative and postoperative sleep 
studies150,212.
Endocrine system
Adequate treatment of hypocalcaemia and thyroid dysfunction is essential22,126,154. Special 
attention to calcium levels at times of biological stress (for example, peri-operatively or 
during puberty, pregnancy or delivery), and vigilance in the neonatal period to prevent 
seizures is crucial22,152,179. Growth hormone deficiency responds well to therapy154. 
Specific growth curves are available156.
Central nervous system
CNS involvement is common in 22q11.2DS. In infancy, neonatal seizures, developmental 
delays, language impairment and autism spectrum disorder each require their own 
management strategies. These include infant stimulation, total communication strategies 
beginning in infancy and specialized educational interventions. Neuromotor deficits, 
especially in the domains of balance and coordination, occur early and require 
remediation171,213,214. The diagnosis of autism spectrum disorder may be relevant to clarify 
limitations in social interaction and communication and the presence of repetitive 
behaviours215. Awareness of these and other developmental deficits is crucial to avoid 
situations in which the environmental expectations exceed the abilities of the child.
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Standard pharmacological and non-pharmacological treatments for attention-deficit, anxiety 
and other mood disorders are effective22,126,216–218, as are standard treatments for major 
psychotic illnesses such as schizophrenia126. Attention to increased risk of seizures and 
movement disorders is important when considering medication choices, and adjunctive or 
prophylactic treatments may be necessary126,189. Standard treatments for epilepsy and 
Parkinson disease seem to be effective126. In light of the prominence of CNS expression, 
targeted pro-active awareness and management of these aspects are required for every 
individual with 22q11.2DS, starting early in life. The available treatment strategies, both 
pharmacological and non-pharmacological, for paediatric and later-onset neuropsychiatric 
disorders are effective and should be applied in accordance with general clinical practice 
guidelines for the associated conditions22,126.
Quality of life
The challenges of intellectual deficits, psychiatric illnesses and other somatic consequences 
of 22q11.2DS can have far-reaching effects on daily functioning and QOL of patients, which 
can result in high burden for the family. Providing adequate support to help optimize 
functioning and QOL of the patient is essential29. As the well-being of the affected 
individual is closely related to the well-being of the caregivers, it is also important to address 
caregivers’ stress and provide support when necessary across the lifespan219,220. As 
disability-related family problems increase with the age of the patient, a growing need for 
counselling, especially for aspects of parenting and discipline, and for treatment can be 
presumed221.
QOL among children with 22q11.2DS is often characterized by struggles in cognitive, social 
and emotional domains222 as compared with healthy peers and those with other chronic 
conditions, such as diabetes, asthma, CHD and cancer. Moreover, children and adolescents 
with 22q11.2DS and repaired CHD have more hospitalizations, worse exercise performance 
and lower reported QOL ratings than seemingly healthy peers201,202,223. Insofar as 
immunodeficiency contributes to infection and hospitalization, more-severe immune 
compromise would be associated with reduced QOL, however, no studies have yet been 
performed. The complexity of multiple affected systems in individuals with 22q11.2DS may 
have a compounding effect on QOL.
With respect to neurocognitive abilities, determining weaknesses as well as relative strengths 
and competencies can facilitate educational and vocational planning and optimize QOL and 
functional outcomes. Depending on overall cognitive capacities (ranging from average to 
intellectual disability), students will follow either typical school placements with educational 
support, often requiring an individualized educational plan, or special education with 
individualized educational plans. Given that the cognitive phenotype can change over 
time181, the intellectual abilities of all patients (regardless of age) should be followed and re-
evaluated at regular intervals. Furthermore, continuous adaptation of expectations and 
learning environments is necessary to provide a balance between individual capacities and 
demands of the environment125 (FIG. 7). In this way, guidance can be implemented at home, 
school and work, whereas unnecessary stress can be averted. Importantly, cognitive decline 
during childhood may be a risk indicator for schizophrenia181, but may also represent a 
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complicating factor in the struggle to maintain the balance between competencies and 
environmental demands.
Functional impairment in adulthood is primarily mediated by more-severe intellectual 
disabilities and psychiatric phenotypes such as schizophrenia205. Functional impairment 
appears unrelated to a history of treated CHD, or mood or anxiety disorders205. Relative 
strengths in activities of daily living and employment are apparent29,205, and support may 
help to compensate for relative weaknesses in social and communication abilities29. 
Individuals tend to have deficits in executive functioning and mental arithmetic224, but 
relatively strong rote memory224,225, so may be well suited to perform structured tasks. 
Receptive and expressive communication may be more effective using indirect methods (that 
is, with a computer or smartphone), as compared with direct verbal communication. Hands-
on training, demonstrations and written instructions may help205.
Adult patients living into middle-age present challenges for long-term care, mainly 
shouldered by their ageing parents, which may cause profound financial, physical and 
emotional stress29,219. Professional agencies, including social work and vocational training, 
can help47. Spouses, siblings and other relatives may also have important roles29,126. Prompt 
recognition and treatment of psychiatric disorders will maximize functioning and improve 
QOL, whereas the integration of medical, educational, behavioural and environmental 
treatment methods and approaches will be necessary to enhance QOL for individuals with 
22q11.2DS and their families.
Outlook
Understanding the pathophysiology
The discovery that the 22q11.2 deletion is the genetic cause of what was previously called 
DiGeorge syndrome led to the identification of the main dosage-sensitive genes (for 
example, TBX1 and CRKL, among other genes) underlying the main developmental 
anomalies. However, all phenotypic features of the syndrome are not fully penetrant in any 
individual patient, and the clinical presentation is remarkably variable. This variability 
remains largely unexplained. It may be that the expression of certain features is more-
directly related to individual gene dosage effects, as identified for TBX1 and CRKL with 
respect to cardiac development. Other features, such as CNS-related pathogenesis, may 
require the effects of multigenic reduced gene dosage within the 22q11.2 deletion interacting 
with permissive variants in modifier genes elsewhere in the genome.
Current research aims to unravel potential pathophysiological roles of allelic variation of 
genes within the 22q11.2 region of the non-deleted chromosome, modifier genes that reside 
outside of the deleted region, somatic mutations, epigenetic phenomena and individual 
characteristics or environmental factors226. Polygenic ‘background’ effects are already 
demonstrated in mouse models that show highly variable expression of key phenotypes 
when the same deletion or individual mutations of deletion region genes are engineered in 
different mouse strains92. The phenotypical variability, even within the same mouse strain, 
as in monozygotic twins with 22q11.2DS29, is also consistent with the role of stochastic 
effects, and potentially epigenetic and other mechanisms. It can be anticipated that ongoing 
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genome-wide association, whole-genome sequencing and expression studies will identify 
genetic modifiers and mechanisms73,74,105,124,227,228.
Features that are easily visible in mouse embryos or human fetuses have been the main focus 
of research thus far. Advances in technologies, and interest, are gradually shifting focus to 
functional changes — that is, studies of neurobehaviour in humans and mouse models. 
22q11.2DS is an interesting model to investigate possible genes, genetic mechanisms and 
central neurotransmitter systems associated with the 22q11.2 region that may contribute to 
the observed cognitive decline in childhood. Genetically engineered mouse models will 
continue to provide the foundation for mechanistic analysis to facilitate understanding of the 
pathogenesis of each of the associated syndromic features and accordingly provide promise 
for improving diagnosis and treatment79. The advantages of studying mouse models of 
22q11.2DS, particularly for changes in cortical circuitry that underlie neurobehavioural 
phenotypes, have recently been summarized79. Large-scale prospective studies of key 
interacting factors will be needed to understand the complex interplay between cognitive, 
mood, psychotic, neuromotor and other neurological symptoms that contribute to the 
variable neuropsychiatric phenotypes associated with 22q11.2DS.
An outstanding question is why 22q11.2DS is the most frequent genomic disorder. Owing to 
the complexity of LCRs229, the rearrangement breakpoints and sequences driving non-allelic 
homologous recombination remain uncharted. Even the latest human genome assembly 
(GRCh38) contains gaps in the LCRs of the 22q11.2 region59,60. A more definitive map may 
help to pinpoint underlying variability in the population. Understanding this variability may 
not only be important for evaluating the reasons for the high prevalence of 22q11.2DS but 
may also stratify individuals at risk for de novo 22q11.2 deletions. In addition, variability of 
LCRs might explain part of the phenotypic variability. Copy number variation within the 
LCR subunits, the precise position of the LCR-mediated rearrangements and the broader 
structural variation among patients may directly affect the expression of the 90 genes and/or 
pseudogenes located within the LCRs and/or indirectly affect expression of flanking genes.
Importantly, if mutations that lead to other autosomal recessive disorders are present in the 
non-deleted allele, they can be unmasked owing to the deletion of the other 22q11.2 allele 
(for example, Bernard–Soulier and CEDNIK syndromes)68,230 (FIG. 8).
22q11.2DS as a model system
22q11.2DS has been shown to be a good model system over the past 25 years for human 
microdeletions and their related genomic disorders or syndromes. This work has helped to 
demonstrate how microdeletions could explain many syndromes with known, but extremely 
rare, microscopically visible deletions, similar to Williams–Beuren syndrome (7q11.23 
deletion), WAGR syndrome (Wilms’ tumour, aniridia, genitourinary malformation and 
retardation; 11p13 deletion) and Wolf–Hirschhorn syndrome (4p16.3 deletion). In addition, 
22q11.2DS has demonstrated how chromosomally engineered and subsequently transgenic 
mice could be used to identify a causative gene (or genes) in copy number variation 
disorders.
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The combination of human genetics with developmental analysis of mouse models also 
demonstrated how phenotypic overlap at the clinical level could be recapitulated in specific 
anatomical defects at the embryonic level (for example, Tbx1-mutant and Chd7-mutant 
mice, and 22q11.2DS and CHARGE syndrome in humans, respectively). More-detailed 
analysis of the role of Tbx1 in mice has been fundamental in expanding our knowledge of 
the role of the second heart field lineage in congenital heart malformations and has informed 
other areas, such as thymic development (including the induction of thymic cells from stem 
cells).
22q11.2DS is also a very strong genetic cause of psychiatric abnormalities, in particular 
schizophrenia, and thus serves as a good model of this complex condition to study the 
trajectory from genetic risk to psychiatric expression231. Patients with 22q11.2DS with 
psychiatric disorders may have no formal intellectual disability. The association with a 
defined genetic cause, as for complex anatomic anomalies such as cardiac defects, has 
facilitated human and animal studies of neurodevelopment and neurofunctional changes to 
schizophrenia and other psychotic disorders.
Thus, 22q11.2DS is a model for understanding common congenital anomalies, rare and 
common psychiatric and other medical conditions and developmental differences, and may 
provide insight into translational strategies across the lifespan, not only for patients with 
22q11.2DS but also for those with these individual conditions in the general population.
Management
Animal models provide promise in the development of pharmaceutical agents to treat 
22q11.2DS-related phenotypes. Simple model organisms (for example, Caenorhabditis 
elegans, Drosophila and zebrafish) are particularly suited to high-throughput screening of 
chemical libraries for potential drug development89. More data are needed on treatment 
response and caveats in 22q11.2DS for all associated conditions and treatment 
modalities189,201,202. Importantly, current cohorts of patients with 22q11.2DS have become 
sufficiently large to begin examining the effect of current and novel treatment strategies in 
adequately powered clinical trials.
Prevention, diagnosis and screening
Lack of recognition of the condition and/or lack of familiarity with genetic testing methods, 
together with the wide variability of expression, delays diagnosis both prenatally and 
postnatally. Early diagnosis offers multiple advantages and could improve preparedness and 
outcomes while potentially reducing medical, emotional and fiscal (and therefore societal) 
costs.
Although helpful in the initial recognition of the syndrome, relying on congenital features as 
‘characteristic’ of 22q11.2DS would now be considered inadequate to capture the variable 
expression of the 22q11.2 deletion across the lifespan. Old names for the syndrome 
perpetuate the myth that a patient ‘must’ have one or more of these features, promoting the 
often lengthy diagnostic odyssey endured by many patients, families and clinicians. Until 
there is completely unbiased ascertainment — that is, identification of the 22q11.2 deletion 
by screening all live births — with lifetime follow-up of emerging features, all prevalence 
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figures for associated features must be assumed to be only gross estimates, probably biased 
to more-severe expression22,126.
Non-invasive prenatal screening for fetal aneuploidy detection is an increasingly offered 
service, with the ability to detect smaller fetal (and sometimes maternal) segmental 
aneuploidies, such as 22q11.2 deletions197,232. Further technological advances are likely to 
improve accuracy. Prenatal detection of 22q11.2DS will enable future parents to make 
informed choices, prepare for obstetrical and neonatal management, and provide the 
opportunity to improve survival and outcome157,179. The unbiased detection of 22q11.2DS 
will establish true incidence, will enable longitudinal medical course surveillance from the 
prenatal period and will allow for earlier intervention.
Several technologies have been tested for sensitivity and specificity in the setting of newborn 
screening233–235. All rely on DNA detection and are therefore both robust yet sensitive to 
settings where DNA may be limited or degraded (such as when there is low white blood cell 
count or improper sample storage). Strategies range from genome-wide deletion, duplication 
and rearrangement approaches to specific detection of the 22q11.2 deletion. All have shown 
technical feasibility. The larger hurdle will be to establish the political will to implement one 
or more strategies in a pilot approach in a real-life setting. The usual test for application of a 
new screening test is demonstration that early detection improves outcomes. Efforts are 
underway to establish this connection and a powerful grass roots movement has supported 
the newborn screening initiative.
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Box 1
General principles to manage 22q11.2 deletion syndrome
• Early diagnosis and effective treatment of each condition improves general 
outcome
• Attention to the multi-system nature of 22q11.2 deletion syndrome is key
• Goals to promote an optimal quality of life and functioning for the individual 
patient
• Appreciation of the level of the individual’s neurocognitive abilities when 
providing advice, regardless of chronological age
• Family members and caregivers to be included, as much as possible, in 
developing a health care plan for patients of all ages as allies in maximizing the 
understanding of the illness and recommended treatments and follow-up
• Relatives and social service agents can be instrumental in implementing health 
care recommendations for extended family members, in particular children, 
when the 22q11.2 deletion is familial
• Times of transition (for example, from paediatric to adult care) require special 
attention to prevent gaps in care
• The effect of treatment for one condition may positively or negatively impact 
another condition
• Patients benefit from a single invested health care manager or team who will 
coordinate care and facilitate communication between providers
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Figure 1. Chromosome 22 idiogram
Cytogenetic representation of chromosome 22 showing the short (p) and long (q) arms along 
with the centromere, which functions to separate both arms. Chromosome 22 is an 
acrocentric chromosome, as indicated by the two horizontal lines in the p arm. The 22q11.2 
deletion occurs on the long arm of one of the two chromosomes, depicted by dashed lines in 
the 22q11.2 band. The position of the two low copy repeats (LCRs) on 22q11.2 (LCR22A 
and LCR22D), which flank the typical 3-Mb deletion, are indicated.
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Figure 2. Low copy repeats and genes within the 22q11.2 deletion
Schematic representation of the 3-Mb 22q11.2 region that is commonly deleted in 22q11.2 
deletion syndrome, including the four low copy repeats (LCR22s) that span this region 
(LCR22A, LCR22B, LCR22C and LCR22D). Common commercial probes for fluorescence 
in situ hybridization (FISH) are indicated (N25 and TUPLE). The protein-coding and 
selected non-coding (*) genes are indicated with respect to their relative position along 
chromosome 22 (Chr22). T-box 1 (TBX1; green box) is highlighted as the most widely 
studied gene within the 22q11.2 region. Mutations in this gene have resulted in conotruncal 
cardiac anomalies in animal models and humans. Known human disease-causing genes that 
map to the region are indicated in grey boxes. These include proline dehydrogenase 1 
(PRODH; associated with type I hyperprolinaemia), solute carrier family 25 member 1 
(SLC25A1; encoding the tricarboxylate transport protein and is associated with combined 
D-2- and L-2-hydroxyglutaric aciduria), platelet glycoprotein Ib β-polypeptide (GP1BB; 
associated with Bernard–Soulier syndrome), scavenger receptor class F member 2 
(SCARF2; associated with Van den Ende–Gupta syndrome), synaptosomal-associated 
protein 29 kDa (SNAP29; associated with cerebral dysgenesis, neuropathy, ichthyosis and 
palmoplantar keratoderma (CEDNIK) syndrome), and leucine-zipper-like transcription 
regulator 1 (LZTR1; associated with schwannomatosis 2). Further details on the location of 
non-coding RNAs and pseudogenes in the 22q11.2 region may be found in Guna et al.89. 
Common 22q11.2 deletions are shown, with the typical 3-Mb deletion flanked by LCR22A 
and LCR22D (LCR22A– LCR22D) on top and the nested deletions, with their respective 
deletion sizes indicated below. Each of the deletions portrayed is flanked by a particular 
LCR22. Those rare deletions not mediated by LCRs are not shown. AIF3M, apoptosis-
inducing factor mitochondrion-associated 3; ARVCF, armadillo repeat gene deleted in 
velocardiofacial syndrome; CDC45, cell division cycle 45; Cen, centromere; CLDN5, 
claudin 5; CLTCL1, clathrin heavy chain-like 1; COMT, catechol-O-methyltransferase; 
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CRKL, v-crk avian sarcoma virus CT10 oncogene homologue-like; DGCR, DiGeorge 
syndrome critical region; GNB1L, guanine nucleotide-binding protein (G protein), β-
polypeptide 1-like; GSC2, goosecoid homeobox 2; HIC2, hypermethylated in cancer 2; 
HIRA, histone cell cycle regulator; KLHL22, kelch-like family member 22; LINC00896, 
long intergenic non-protein-coding RNA 896; LOC101927859, serine/arginine repetitive 
matrix protein 2-like; CCDC188, coiled-coil domain-containing 188; LRRC74B, leucine-
rich repeat-containing 74B; MED15, mediator complex subunit 15; mir, microRNA; 
MRPL40, mitochondrial ribosomal protein L40; P2RX6, purinergic receptor P2X ligand-
gated ion channel 6; PI4KA, phosphatidylinositol 4-kinase catalytic-α; RANBP1, Ran-
binding protein 1; RTN4R, reticulon 4 receptor; SEPT7, septin 7; SERPIND1, serpin 
peptidase inhibitor clade D (heparin co-factor) member 1; TANGO2, transport and golgi 
organization 2 homologue; THAP7, THAP domain-containing 7; TRMT2A, tRNA 
methyltransferase 2 homologue A; TSSK2, testis-specific serine kinase 2; TXNRD2, 
thioredoxin reductase 2; UFD1L, ubiquitin fusion degradation 1-like; USP41, ubiquitin-
specific peptidase 41; ZDHHC8, zinc-finger DHHC-type-containing 8; ZNF74, zinc-finger 
protein 74.
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Figure 3. 22q11.2 non-allelic homologous recombination
Diagram of two different types of meiotic non-allelic homologous recombination events that 
can occur between low copy repeats on chromosome 22 (LCR22s). Rearrangements between 
LCR22A and LCR22D are indicated (A and D) on each allele (blue versus yellow). 
Interchromosomal events (left) occur between paralogous LCR22s (A and D) in two 
different alleles owing to >99% sequence identity of direct repeats (‘X’ shows the crossover 
of the two chromosomes). The hybrid LCR22 is shown as half yellow and half blue. This 
process results in a duplication or deletion of intervening genes in resulting gametes. 
Intrachromosomal recombination events (right) result from crossing over (indicated by ‘X’) 
within one allele, resulting in a deletion (left) or a ring chromosome (right); the ring 
chromosome is not viable.
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Figure 4. Development of the cardiovascular and pharyngeal structures affected in 22q11.2 
deletion syndrome
a | The schematic ventral view of an embryonic day 7.5 (E7.5) mouse embryo shows the 
relationship of the cardiac crescent to the head folds and also depicts the distinct cellular 
fields termed the first heart field and the second heart field (SHF). Within the second heart 
field, the anterior segment (aSHF) contributes to the outflow tract (OFT) and the right 
ventricle (RV) of the heart, whereas the posterior segment (pSHF) contributes to the inflow 
of the heart. b | Cardiac neural crest cells (NCCs) delaminate from the hindbrain and migrate 
ventrolaterally to populate the pharyngeal arches. The T-box transcription factor TBX1 is 
required within the pharyngeal surface ectoderm to regulate as yet unknown signalling 
pathways, which pattern the cardiac NCCs (dashed arrow). The pharyngeal endoderm and 
cardiac NCCs interact in the formation of the thymus and parathyroid glands. c | Lateral 
view of an E10.5 mouse embryo. The cardiac neural crest arises from the neural tube at the 
level between the otic placode and somite three, and migrates ventrolaterally to populate the 
pharyngeal arches, interacting with the core mesoderm and ultimately contributing the 
smooth muscle cells to the remodelling arch arteries. The caudal stream enters the OFT. d | 
Schematic presentation of the cell lineage that contributes to the OFT of the heart at 
approximately E10.5. (1) Cells derived from the aSHF enter the OFT where they contribute 
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to the myocardium and endocardium. (2) These cells interact with cardiac NCCs that 
migrate in from the pharyngeal arch region. Signals to the cardiac neural crest are also 
received from the pharyngeal epithelium. Disruption to these cellular contributions or 
interactions can result in a common arterial trunk, alignment defects or ventricular septation 
defects.
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Figure 5. Organ and system involvement in 22q11.2 deletion syndrome
22q11.2 deletion syndrome leads to significant morbidity (and some premature mortality), 
with frequent multi-organ system involvement, such as cardiac and palatal abnormalities, 
immune differences, endocrine and gastrointestinal problems, and later-onset conditions 
across the lifespan including variable cognitive deficits and psychiatric illness that is 
attributable to functional brain changes. Less-frequent manifestations, when present, 
contribute to substantial morbidity (examples include: idiopathic seizures; polymicrogyria; 
sclerocornea; coloboma; deafness; choanal atresia; laryngeal cleft or web; tracheo-
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oesophageal fistula; hypothyroidism or hyperthyroidism; juvenile rheumatoid arthritis; 
idiopathic thrombocytopenia; autoimmune haemolytic anaemia; craniosynostosis; scoliosis; 
intestinal malrotation; Hirschsprung disease; and imperforate anus). Minor malformations 
generally confer little indisposition but may enhance ascertainment. These generally include: 
mild dysmorphic craniofacial features, such as hooded eyelids, auricular anomalies, nasal 
differences including a dimple or crease, and asymmetric crying facies; and, cervical and 
thoracic vertebral anomalies or butterfly vertebrae, arachnodactyly, camptodactyly, 2–3 toe 
syndactyly and polydactyly (preaxial and postaxial of the hands and postaxial of the feet).
McDonald-McGinn et al. Page 42
Nat Rev Dis Primers. Author manuscript; available in PMC 2016 June 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Craniofacial features associated with 22q11.2 deletion syndrome
Patients with 22q11.2 deletion syndrome (22q11.2DS), shown here from infancy through to 
adulthood, demonstrate variability of associated craniofacial features — most with few 
recognizable dysmorphia (part a). A person with 22q11.2DS has a 50% recurrence risk with 
each pregnancy for this microdeletion syndrome, but some adults only come to attention 
following the diagnosis in a child with associated features, as in these unrelated nuclear 
families (daughter and father (part b) and son and mother (part c)). When viewed 
individually, some craniofacial features provide important clues to the diagnosis, for 
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example, microstomia and asymmetric crying facies (part d), and malar flatness and 
micrognathia (part e). External eye findings (part f) may include upslanting palpebral 
fissures and hypertelorism (1), hooded eyelids and/or ptosis (2) and mild epicanthal folds 
(3). Nasal features (part g) may include a bulbous nasal tip with hypoplastic alae nasi (4) 
often with a nasal dimple or crease with or without a faint haemangioma (5). Auricular 
differences (part h) frequently include thick overfolded, squared-off and crumpled helices, 
microtic, cupped or posteriorly rotated ears, attached lobes and preauricular pits or tags 
(arrows).
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Figure 7. Developmental trajectory
As the child with 22q11.2 deletion syndrome (22q11.2DS) ages, the discrepancy between 
developmental level (based on chronological age) and environmental demands widens owing 
to associated neurocognitive and behavioural developmental deficits. Note that IQ decline 
observed in 22q11.2DS may not only be due to a relative but also to an absolute decline in 
cognitive abilities.
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Figure 8. Associated autosomal recessive conditions on 22q11.2
A deletion on 22q11.2 in combination with a mutation in a single gene on the other allele 
can unmask an autosomal recessive condition, for example, Bernard–Souilier syndrome 
(platelet glycoprotein Ib β-polypeptide (GP1BB)) and cerebral dysgenesis, neuropathy, 
ichthyosis and palmoplantar keratoderma (CEDNIK) syndrome (synaptosomal-associated 
protein 29 kDa (SNAP29)).
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